|
ABOUT US
Founded in December 2003, Neogenix Oncology is a clinical stage biotechnology company focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. The company’s antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. Neogenix Oncology is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. By marrying this platform with today’s breakthrough technologies, the company is developing antibody therapeutics that could change the way we detect and treat cancer. |
ADDITIONAL INFORMATION
For more information, please contact: RoseMarie Terenzio RMT PR Management 212-414-1909 or 917-913-7226 (cell) rterenzio@rmtpr.com |
 |